RemedyMD

Pediatric Diabetes Registry – A Milestone for Diabetes Research

RemedyMD’s solution aims to solve $174 billion problem by shifting focus towards research based on more comprehensive scientific evidence

 

Sandy, UT -- (SBWIRE) -- 12/09/2009 -- RemedyMD, the leading provider of Disease Registry software, today announced the first nationwide Pediatric Diabetes Registry. The new registry was developed to help clinicians and researchers identify which interventions are most appropriate for specific patient populations.

Details about the registry: http://www.remedymd.com/cer100/pediatric_diabetes.html

RemedyMD’s pediatric diabetes registry tracks patient outcomes over time including changes in HgA1c, LDL cholesterol and insulin levels. Researchers and clinicians can also track HgA1c by medication or medication class and easily generate reports showing results by multiple demographic or clinical indicators such as:

* Age
* Gender
* Ethnicity
* Insurance type

The new registry contains 1,500+ pediatric diabetes-specific fields for physicians, nurses, social workers, and dietitians to support all elements of pediatric diabetes research. Additionally, the registry includes all of the applications, data infrastructure, and tools that clinicians and researchers need to gather, synthesize and analyze both phenotypic and genotypic data simultaneously.

“Our experience has shown when you view and report across all data types at the same time, you discover patterns and associations that are indistinguishable using traditional methodologies” said Gary D. Kennedy, Founder and CEO of RemedyMD.

RemedyMD’s new pediatric diabetes registry includes a comprehensive set of electronic data collection (EDC) forms that are specific to pediatric diabetes research, ad hoc reporting capability, and pattern recognition tools that assist users in identifying the most effective treatment options.

In support of this initiative RemedyMD is seeking additional partners who have existing data that addresses the specific needs of pediatric diabetes researchers. All institutions involved in comparative effectiveness research that are planning on submitting grant proposals for AHRQ funding are invited to visit: http://www.remedymd.com/cer100/pediatric_diabetes.html

RemedyMD Resources:
Resource Kit for Comparative Effectiveness Research: http://www.remedymd.com/cer_kit.html
Ways to Leverage Pediatric Diabetes Registry: http://www.remedymd.com/cer100/pediatric_diabetes.html
Comparative Effectiveness Research: http://www.remedymd.com/cer_home.html
Disease Registry Software: http://www.remedymd.com/registries_home.html

About RemedyMD
RemedyMD® is the leading provider of specialized software applications, tools, and data necessary for comparative effectiveness research with more than 100 pre-built clinical, disease, and patient registry software applications. RemedyMD solutions are personalized to the institution, the clinical specialty, and to the individual provider’s preferences enabling researchers to identify new patterns, facilitate new discoveries, and improve medical outcomes. For more information, visit http://www.RemedyMD.com.

Press Contact:
Lane Peterson
RemedyMD
SALT LAKE CITY, US
801.733.3383
lpeterson@remedymd.com
http://www.RemedyMD.com